OrbiMed
Global healthcare investment firm focused on driving innovation and improving patient outcomes.
About
From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $13 billion across public and private company investments worldwide.
Key facts
At-a-glance profile data
- Website
- orbimed.com
- Type
- Venture Capital
- Headquarters
- New York City, United States
- Funds raised
- $17.0B
- Portfolio companies
- 84
- Stages
- SeedSeries ASeries BSeries CSeries E
- Cheque size
- $5M to $200M
- Sector focus
- HealthcareLungTreatmentBiotechCystic Fibrosis
Recent investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 15 Apr 2026 | Terremoto Biosciences | Series C | $108M |
| 8 Apr 2026 | Sidewinder Therapeutics | Series B | $137M |
| 3 Sept 2025 | Treeline Biosciences | Series B | $200M |
| 11 Jun 2025 | VISEN Pharmaceuticals | Undisclosed round | Undisclosed |
| 23 Jul 2024 | Magenta Medical | Series D | $105M |
| 15 May 2024 | Orqai | Undisclosed round | $30M |
| 27 Sept 2023 | Evozyne | Series B | $81M |
| 23 Aug 2023 | 80073 | Series D | $75M |
| 8 Jun 2023 | Upstream Bio | Series B | $200M |
| 3 May 2023 | Magenta Medical | Series C | $55M |
Frequently asked
What companies has OrbiMed invested in?
OrbiMed has invested in Terremoto Biosciences, Sidewinder Therapeutics, Treeline Biosciences, VISEN Pharmaceuticals, Magenta Medical and 79 more.